Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 8;28(152):190054.
doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.

Severe T2-high asthma in the biologics era: European experts' opinion

Ian Pavord  1 , Thomas Bahmer  2 , Fulvio Braido  3 , Borja G Cosío  4   5 , Marc Humbert  6   7 , Marco Idzko  8 , Lukasz Adamek  9
Affiliations
Review

Severe T2-high asthma in the biologics era: European experts' opinion

Ian Pavord et al. Eur Respir Rev. .

Abstract

The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: I. Pavord reports personal fees (speaker's honoraria, travel expenses and honoraria for attending advisory boards) from AstraZeneca, GSK, Boehringer Ingelheim and Teva, personal fees (speaker fees, fees for advisory boards and travel expenses for attending international meetings) from Chiesi, personal fees for advisory boards from Sanofi/Regeneron, Merck, Novartis, Knopp, Afferent and Roche/Genentech, and personal speaker fees from Circassia and Mundipharma, as well as research grants from Chiesi and Afferent, all outside the submitted work. Conflict of interest: T. Bahmer reports personal fees and other support (including compensation for travel expenses) from Chiesi, AstraZeneca, Roche, GlaxoSmithKline and Novartis, outside the submitted work. Conflict of interest: F. Braido reports personal fees (speaker's honoraria and travel expenses) from AstraZeneca, outside the submitted work. Conflict of interest: B.G. Cosío reports personal fees from AstraZeneca during the conduct of the study; as well as personal fees from AstraZeneca, Teva and Mundipharma, and grants and personal fees from Chiesi, Boehringer Ingelheim, Menarini and Novartis, outside the submitted work. Conflict of interest: M. Humbert reports personal fees from AstraZeneca, GSK, Novartis, Roche, Sanofi and Teva, during the conduct of the study. Conflict of interest: M. Idzko has nothing to disclose. Conflict of interest: L. Adamek is an employee of AstraZeneca.

References

    1. Humbert M, Busse W, Hanania NA. Controversies and opportunities in severe asthma. Curr Opin Pulm Med 2018; 24: 83–93. - PubMed
    1. Price D, Bjermer L, Bergin DA, et al. . Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy 2017; 10: 209–223. - PMC - PubMed
    1. Bel EH, Wenzel SE, Thompson PJ, et al. . Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197. - PubMed
    1. Nair P, Wenzel S, Rabe KF, et al. . Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448–2458. - PubMed
    1. Rabe KF, Nair P, Brusselle G, et al. . Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485. - PubMed

Publication types